Abstract
Background: Malignant mesothelioma (MM) is an aggressive pleural tumor which is difficult to diagnose in its early stages. Thus, biomarkers for MM including soluble mesothelin-related protein (SMRP) are currently an area of intense research interest. However, SMRP is affected by several factors other than malignancy which need to be taken into account in the individual patient. This study aimed to evaluate factors required to adjust SMRP levels for such variables and produce a useful prediction equation for clinical application.
Methods: Serum SRMP levels were measured in 535 subjects formerly exposed to asbestos and silica, including many with asbestos-related disorders (ARDs). Linear regression analyses were used to quantify the strength and “direction” of the relationship between SMRP and several independent variables, and 2×2 tables were used to determine the diagnostic accuracy of SMRP levels, taking into account clinical variables.
Results: SMRP levels were affected by age and glomerular filtration rate (GFR), which were strong confounders in this study. Body mass index (BMI) was also an initial confounder but lost significance after other factors were taken into account. SMRP was also affected by smoking. Poor sensitivity (15.1%) for SMRP values among subjects with non-malignant asbestos-related disorders was found when compared to currently healthy subjects with a history of asbestos exposure.
Conclusions: The present study proposes an equation based on age and GFR to improve diagnostic accuracy of SMRP. The poor sensitivity of SMRP found in this study suggests that further work is needed to find new candidate biomarkers for diagnosing early stage MM.
This study was supported by the Kosin Medical School and the Lesley Pockley Clinical Research Trust.
Conflict of interest statement
Authors’ conflict of interest disclosure: The authors stated that there are no conflicts of interest regarding the publication of this article. Research support played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
Research funding: None declared.
Employment or leadership: None declared.
Honorarium: None declared.
References
1. Martino D, Pass HI. Integration of multimodality approaches in the management of malignant pleural mesothelioma. Clin Lung Cancer 2004;5:290–8.10.3816/CLC.2004.n.008Search in Google Scholar PubMed
2. Hyland RA, Ware S, Johnson AR, Yates DH. Incidence trends and gender differences in malignant mesothelioma in New South Wales, Australia. Scand J Work Environ Health 2007;33: 286–92.10.5271/sjweh.1145Search in Google Scholar PubMed
3. Creaney J, Yeoman D, Demelker Y, Segal A, Musk AW, Skates SJ, et al. Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma. J Thorac Oncol 2008;3: 851–7.10.1097/JTO.0b013e318180477bhttp://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000258447300007&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f3Search in Google Scholar PubMed
4. Cristaudo A, Bonotti A, Simonini S, Vivaldi A, Guglielmi G, Ambrosino N, et al. Combined serum mesothelin and plasma ostepontin measurements in malignant pleural mesothelioma. J Thorac Oncol 2011;6:1587–93.http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000294008000021&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f310.1097/JTO.0b013e31821e1c08Search in Google Scholar PubMed
5. Hollevoet K, Nackaerts K, Thimpont J, Germonpré P, Bosquée L, De Vuyst P, et al. Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma. Am J Respir Crit Care Med 2010;181:620–5.http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000280446500016&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f310.1164/rccm.200907-1020OCSearch in Google Scholar PubMed
6. Park EK, Sandrini A, Yates DH, Creaney J, Robinson BW, Thomas PS, et al. Soluble mesothelin-related protein in an asbestos-exposed population: the dust diseases board cohort study. Am J Respir Crit Care Med 2008;178:832–7.http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000259932600010&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f310.1164/rccm.200802-258OCSearch in Google Scholar PubMed
7. Pass HI, Lott D, Lonardo F, Harbut M, Liu Z, Tang N, et al. Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med 2005;353:1564–73.10.1056/NEJMoa051185Search in Google Scholar PubMed
8. Rai AJ, Flores RM, Mathew A, Gonzalez-Espinoza R, Bott N, Ladanyi M, et al. Soluble mesothelin-related peptides (SMRP) and osteopontin as protein biomarkers for malignant mesothelioma: analytical validation of ELISA based assays and characterization at mRNA and protein levels. Clin Chem Lab Med 2010;48:271–8http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000274286000019&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f3Search in Google Scholar PubMed
9. Schneider J, Hoffmann H, Dienemann H, Herth FJ, Meister M, Muley T. Diagnostic and prognostic value of soluble mesothelin-related proteins in patients with malignant pleural mesothelioma in comparison with benign asbestosis and lung cancer. J Thorac Oncol 2008;3:1317–24.http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000261113500016&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f310.1097/JTO.0b013e318187491cSearch in Google Scholar PubMed
10. Beyer HL, Geschwindt RD, Glover CL, Tran L, Hellstrom I, Hellstrom KE, et al. MESOMARK: a potential test for malignant pleural mesothelioma. Clin Chem 2007;53:666–72.http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000245640400017&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f310.1373/clinchem.2006.079327Search in Google Scholar PubMed
11. Boudville N, Paul R, Robinson BW, Creaney J. Mesothelin and kidney function-analysis of relationship and implications for mesothelioma screening. Lung Cancer 2011;73:320–4.10.1016/j.lungcan.2011.01.011http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000294101000012&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f3Search in Google Scholar PubMed
12. Hollevoet K, Nackaerts K, Thas O, Thimpont J, Germonpré P, De Vuyst P, et al. The effect of clinical covariates on the diagnostic and prognostic value of soluble mesothelin and megakaryocyte potentiating factor. Chest 2012;141:477–84.http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000299917900027&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f310.1378/chest.11-0129Search in Google Scholar PubMed
13. Park EK, Thomas PS, Creaney J, Johnson AR, Robinson BW, Yates DH. Factors affecting soluble mesothelin related protein levels in an asbestos-exposed population. Clin Chem Lab Med 2010;48:869–74.http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000279342700021&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f3Search in Google Scholar
14. Weber DG, Johnen G, Taeger D, Weber A, Gross IM, Pesch B, et al. Assessment of confounding factors affecting the tumor markers SMRP, CA125, and CYFRA21-1 in serum. Biomark Insights 2010;5:1–8.10.4137/BMI.S3927Search in Google Scholar PubMed PubMed Central
15. Hollevoet K, Bernard D, De Geeter F, Walgraeve N, van den Eeckhaut A, Vanholder R, et al. Glomerular filtration rate is a confounder for the measurement of soluble mesothelin in serum. Clin Chem 2009;55:1431–3.10.1373/clinchem.2008.121913Search in Google Scholar PubMed
16. American Thoracic Society. Diagnosis and initial management of nonmalignant diseases related to asbestos. Am J Respir Crit Care Med 2004;170:691–715.10.1164/rccm.200310-1436STSearch in Google Scholar PubMed
17. Amati M, Tomasetti M, Scartozzi M, Mariotti L, Alleva R, Pignotti E, et al. Profiling tumor-associated markers for early detection of malignant mesothelioma: an epidemiologic study. Cancer Epidemiol Biomarkers Prev 2008;17:163–70.http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000252503900021&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f310.1158/1055-9965.EPI-07-0607Search in Google Scholar PubMed
18. Creaney J, Christansen H, Lake R, Musk AB, de Klerk N, Robinson BW. Soluble mesothelin related protein in mesothelioma. J Thorac Oncol 2006;1:172–4.10.1097/01243894-200602000-00013Search in Google Scholar
19. Creaney J, van Bruggen I, Hof M, Segal A, Musk AW, de Klerk N, et al. Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma. Chest 2007;132:1239–46.http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000250254000024&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f310.1378/chest.07-0013Search in Google Scholar PubMed
20. Creaney J, Yeoman D, Naumoff LK, Hof M, Segal A, Musk AW, et al. Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma. Thorax 2007;62:569–76.http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000247620800004&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f310.1136/thx.2006.068114Search in Google Scholar PubMed PubMed Central
21. Cristaudo A, Foddis R, Vivaldi A, Guglielmi G, Dipalma N, Filiberti R, et al. Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer. Clin Cancer Res 2007;13:5076–81.10.1158/1078-0432.CCR-07-0629http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000249287700020&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f3Search in Google Scholar PubMed
22. Di Serio F, Fontana A, Loizzi M, Capotorto G, Maggiolini P, Mera E, et al. Mesothelin family proteins and diagnosis of mesothelioma: analytical evaluation of an automated immunoassay and preliminary clinical results. Clin Chem Lab Med 2007;45: 634–8.http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000247005900011&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f3Search in Google Scholar
23. Grigoriu B, Chahine B, Zerimech F, Grégoire M, Balduyck M, Copin MC, et al. Serum mesothelin has a higher diagnostic utility than hyaluronic acid in malignant mesothelioma. Clin Biochem 2009;42:1046–50.http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000267274300018&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f310.1016/j.clinbiochem.2009.03.007Search in Google Scholar PubMed
24. Grigoriu BD, Scherpereel A, Devos P, Chahine B, Letourneux M, Lebailly P, et al. Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment. Clin Cancer Res 2007;13:2928–35.10.1158/1078-0432.CCR-06-2144http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000246572600016&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f3Search in Google Scholar PubMed
25. Pass HI, Wali A, Tang N, Ivanova A, Ivanov S, Harbut M, et al. Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions. Ann Thorac Surg 2008;85:265–72.10.1016/j.athoracsur.2007.07.042http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000251837400038&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f3Search in Google Scholar PubMed
26. Rodríguez Portal JA, Rodríguez Becerra E, Rodríguez Rodríguez D, Alfageme Michavila I, Quero Martínez A, Diego Roza C, et al. Serum levels of soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related pleural disease: relation with past asbestos exposure. Cancer Epidemiol Biomarkers Prev 2009;18:646–50.10.1158/1055-9965.EPI-08-0422http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000263547800037&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f3Search in Google Scholar PubMed
27. Scherpereel A, Grigoriu B, Conti M, Gey T, Grégoire M, Copin MC, et al. Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma. Am J Respir Crit Care Med 2006;15:1155–60.10.1164/rccm.200511-1789OCSearch in Google Scholar PubMed
28. Van den Heuvel MM, Korse CM, Bonfrer JM, Bass P. Non-invasive diagnosis of pleural malignancies: the role of tumour markers. Lung Cancer 2008;59:350–4.http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000255606900008&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f310.1016/j.lungcan.2007.08.030Search in Google Scholar PubMed
29. Hollevoet K, Reitsma JB, Creaney J, Grigoriu BD, Robinson BW, Scherpereel A, et al. Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis. J Clin Oncol 2012;30:1541–9.10.1200/JCO.2011.39.6671http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000303859400026&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f3Search in Google Scholar PubMed PubMed Central
30. Wheatley-Price P, Yang B, Patsios D, Patel D, Ma C, Xu W, et al. Soluble-mesothelin-related peptide and osteopontin as markers of response in malignant mesothelioma. J Clin Oncol 2010;28:3316–22.10.1200/JCO.2009.26.9944http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000279637600018&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f3Search in Google Scholar PubMed
31. Chapman EA, Thomas PS, Stone E, Lewis C, Yates DH. A breath test for malignant mesothelioma using an electronic nose. Eur Respir J 2011 Dec 19 [Epub ahead of print]. DOI: 10.1183/09031936.00040911.10.1183/09031936.00040911http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000307291700025&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f3Search in Google Scholar PubMed
32. Yamada S, Tabata C, Tabata R, Fukuoka K, Nakano T. Clinical significance of pleural effusion mesothelin in malignant pleural mesothelioma. Clin Chem Lab Med 2011;49:1721–6.http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000296591500019&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f3Search in Google Scholar PubMed
©2012 by Walter de Gruyter Berlin Boston
